NCT01223222View on ClinicalTrials.gov

A Study to Evaluate Safety, Tolerability and Efficacy of Lytixar™ (LTX-109) on Uncomplicated, Gram-positive, Skin Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions
Gram-positive, Skin InfectionsMild Eczema/DermatosesAtopic Dermatitis
Interventions
DRUG

LTX-109

Topical administration. 3 times daily. 5 days.

Trial Locations (4)

3529

Miskolci Semmelweis Ignác Egészegügyi Központ és, Miskolc

4032

Debreceni Egyetem Orvos-és Egészségtudományi, Debrecen

6720

Szeged Univesrity Hospital, Szeged

7624

Pécsi Tudományegyetem általános Orvostudom´nyi Centum, Pécs

Sponsors

Lead Sponsor

Lytix Biopharma AS
All Listed Sponsors
lead

Lytix Biopharma AS

INDUSTRY